Prof.

MIRANDOLA Prisco

Professore di I fascia
  • Curriculum Vitae
  • Teaching
  • Appointments
  • Research

Curriculum Prof. Mirandola Prisco

Born in Rovigo on 22/08/1969
MsC Biological Sciences (1992)

1. Academic position:
a) macro-sector competition 05H, 05H2 area competition; scientific-disciplinary sector BIO/16 (Human Anatomy);
b) length of tenure;
Associate Professor from 11/01/2009 (DR 925 of 04.05.2010)
c) the university and the department;
University of Parma, Faculty of Medicine, Department of Anatomy, Pharmacology and Forensic Medical Sciences
d) previously held positions in the same university or other.
Assistant Professor from 1/11/2001 at the 'University of Parma, Faculty of Medicine, Department of Anatomy, Pharmacology and Forensic Medical Sciences

2. Scientific publications:
a) Overall list of publications, with particular reference to consecutive preceding five years
the date of publication of the decree referred to in Article 6, paragraph 1 of the Regulations;
Total number of publications = 72
Index = 26 H and Citations Total 1919 (Scopus)
Index = 27 H and Citations Total 1859 (ISI Web of Knowledge - Thomson Reuters)
H = 29 index and total citations in 2451 (Google Scholar)
IF2010 cumulative > 414
IF2010 mean (of impacted journals) = 5.8

Publications for the past 5 years (since 2007)
No. 23; IF2010 > 99.6

1. Galli D., Volta E., Milioli Ma., Mirandola P., Vanelli M., Brighenti F., Micheloni C., Vaccarezza M., Vitale M., Gobbi G. (2012). Anthropometric outcomes associated with a primary school-based health promotion programme in the Italian city of Parma. Sport Sciences For Health, vol. 7(1), p. 41-46,

2. Dozza B, Gobbi G, Lucarelli E, Pierini M, Bella CD, Frisoni T, Tazzari PL,
Ricci F, Mirandola P, Carubbi C, Giannini S, Donati D, Vitale M. A rapid method
for obtaining mesenchymal stem cells and platelets from bone marrow aspirate. J
Tissue Eng Regen Med. 2012 Jun 19. doi: 10.1002/term.1551. [Epub ahead of print]
PubMed PMID: 22715158.

3. Merighi S, Gessi S, Varani K, Fazzi D, Mirandola P, Borea PA. Cannabinoid
CB(2) receptor attenuates morphine-induced inflammatory responses in activated
microglial cells. Br J Pharmacol. 2012 Mar 16. doi: 10.1111/j.1476-5381.2012.01948.x. [Epub ahead of print] PubMed PMID: 22428664.

4. Mirandola P, Gobbi G, Masselli E, Micheloni C, Di Marcantonio D, Queirolo V,
Chiodera P, Meschi T, Vitale M. Protein kinase Cε regulates proliferation and
cell sensitivity to TGF-1β of CD4+ T lymphocytes: implications for Hashimoto
thyroiditis. J Immunol. 2011 Nov 1;187(9):4721-32. Epub 2011 Sep 30. PubMed PMID:
21964026.

5. Merighi S, Gessi S, Varani K, Simioni C, Fazzi D, Mirandola P, Borea PA.
Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in
microglial cells stimulated with bacterial lipopolysaccharide. Br J Pharmacol.
2012 Mar;165(6):1773-88. doi: 10.1111/j.1476-5381.2011.01673.x. PubMed PMID:
21951063; PubMed Central PMCID: PMC3372829.

6. Mirandola P, Gobbi G, Micheloni C, Vaccarezza M, Di Marcantonio D, Ruscitti F,
de Panfilis G, Vitale M. Hydrogen sulfide inhibits IL-8 expression in human
keratinocytes via MAP kinase signaling. Lab Invest. 2011 Aug;91(8):1188-94. doi:
10.1038/labinvest.2011.76. Epub 2011 May 9. PubMed PMID: 21555999.

7. Gobbi G, Di Marcantonio D, Micheloni C, Carubbi C, Galli D, Vaccarezza M,
Bucci G, Vitale M, Mirandola P. TRAIL up-regulation must be accompanied by a
reciprocal PKCε down-regulation during differentiation of colonic epithelial
cell: implications for colorectal cancer cell differentiation. J Cell Physiol.
2012 Feb;227(2):630-8. doi: 10.1002/jcp.22765. PubMed PMID: 21465464.

8. Arcangeletti MC, Rodighiero I, Mirandola P, De Conto F, Covan S, Germini D,
Razin S, Dettori G, Chezzi C. Cell-cycle-dependent localization of human
cytomegalovirus UL83 phosphoprotein in the nucleolus and modulation of viral gene
expression in human embryo fibroblasts in vitro. J Cell Biochem. 2011
Jan;112(1):307-17. PubMed PMID: 21053310.

9. Gobbi G, Masselli E, Micheloni C, Nouvenne A, Russo D, Santi P, Matteucci A,
Cocco L, Vitale M, Mirandola P. Hypoxia-induced down-modulation of PKCepsilon
promotes trail-mediated apoptosis of tumor cells. Int J Oncol. 2010
Sep;37(3):719-29. PubMed PMID: 20664941.

10. Merighi S, Simioni C, Gessi S, Varani K, Mirandola P, Tabrizi MA, Baraldi PG,
Borea PA. A(2B) and A(3) adenosine receptors modulate vascular endothelial growth
factor and interleukin-8 expression in human melanoma cells treated with
etoposide and doxorubicin. Neoplasia. 2009 Oct;11(10):1064-73. PubMed PMID:
19794965; PubMed Central PMCID: PMC2745672.

11. Zamai L, Galeotti L, Zotto GD, Canonico B, Mirandola P, Papa S.
Identification of a NCR+/NKG2D+/LFA-1(low)/CD94(-) immature human NK cell subset.
Cytometry A. 2009 Nov;75(11):893-901. PubMed PMID: 19743412.

12. Gobbi G, Ricci F, Malinverno C, Carubbi C, Pambianco M, Panfilis G, Vitale M,
Mirandola P. Hydrogen sulfide impairs keratinocyte cell growth and adhesion
inhibiting mitogen-activated protein kinase signaling. Lab Invest. 2009
Sep;89(9):994-1006. Epub 2009 Jun 22. PubMed PMID: 19546851.

13. Mirandola P, Gobbi G, Sponzilli I, Malinverno C, Cavazzoni A, Alfieri R,
Petronini PG, Vitale M. TRAIL-induced apoptosis of FHIT-negative lung cancer
cells is inhibited by FHIT re-expression. J Cell Physiol. 2009 Aug;220(2):492-8.
PubMed PMID: 19418484.

14. Gobbi G, Mirandola P, Carubbi C, Micheloni C, Malinverno C, Lunghi P, Bonati
A, Vitale M. Phorbol ester-induced PKCepsilon down-modulation sensitizes AML
cells to TRAIL-induced apoptosis and cell differentiation. Blood. 2009 Mar
26;113(13):3080-7. Epub 2008 Nov 6. PubMed PMID: 18988868.

15. Gobbi G, Mirandola P, Malinverno C, Sponzilli I, Carubbi C, Ricci F, Binazzi
R, Basso G, Giuliani-Piccari G, Ramazzotti G, Pasquantonio G, Cocco L, Vitale M.
Aberrant expression of B203.13 antigen in acute lymphoid leukemia of B-cell
origin. Int J Oncol. 2008 Aug;33(2):371-4. PubMed PMID: 18636158.

16. Toni R, Mirandola P, Gobbi G, Vitale M. Neuroendocrine regulation and tumor
immunity. Eur J Histochem. 2007;51 Suppl 1:133-8. Review. PubMed PMID: 17703604.

17. Gobbi G, Mirandola P, Sponzilli I, Micheloni C, Malinverno C, Cocco L, Vitale
M. Timing and expression level of protein kinase C epsilon regulate the
megakaryocytic differentiation of human CD34 cells. Stem Cells. 2007
Sep;25(9):2322-9. Epub 2007 Jun 14. PubMed PMID: 17569788.

18. Mirandola P, Gobbi G, Sponzilli I, Pambianco M, Malinverno C, Cacchioli A, De
Panfilis G, Vitale M. Exogenous hydrogen sulfide induces functional inhibition
and cell death of cytotoxic lymphocytes subsets. J Cell Physiol. 2007
Dec;213(3):826-33. PubMed PMID: 17516567.

19. Chiodera P, Volta E, Gobbi G, Milioli MA, Mirandola P, Bonetti A, Delsignore
R, Bernasconi S, Anedda A, Vitale M. Specifically designed physical exercise
programs improve children's motor abilities. Scand J Med Sci Sports. 2008
Apr;18(2):179-87. Epub 2007 May 9. PubMed PMID: 17490452.

20. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E,
Maclennan S, Baraldi PG, Borea PA. Caffeine inhibits adenosine-induced
accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth
factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol
Pharmacol. 2007 Aug;72(2):395-406. Epub 2007 May 8. PubMed PMID: 17488804.

21. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S,
Baraldi PG, Borea PA. Hypoxia inhibits paclitaxel-induced apoptosis through
adenosine-mediated phosphorylation of bad in glioblastoma cells. Mol Pharmacol.
2007 Jul;72(1):162-72. Epub 2007 Mar 30. PubMed PMID: 17400763.

22. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale
M. NK cells and cancer. J Immunol. 2007 Apr 1;178(7):4011-6. Review. PubMed PMID:
17371953.

23. Gessi S, Merighi S, Varani K, Cattabriga E, Benini A, Mirandola P, Leung E,
Mac Lennan S, Feo C, Baraldi S, Borea PA. Adenosine receptors in colon carcinoma
tissues and colon tumoral cell lines: focus on the A(3) adenosine subtype. J Cell
Physiol. 2007 Jun;211(3):826-36. PubMed PMID: 17348028.
------------------------------------------------------------------------------------------------------------------------
Publications prior to the last 5 (five in 2002 - 2006)
n° = 22 IF2010> 107

24. Gobbi G, Sponzilli I, Mirandola P, Tazzari PL, Caimi L, Cacchioli A,
Matteucci A, Giuliani Piccari G, Cocco L, Vitale M. Efficient platelet
delta-granule release induced by [Ca2+]i elevation is modulated by GPIIbIIIa. Int
J Mol Med. 2006 Aug;18(2):309-13. PubMed PMID: 16820939.

25. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S,
Baraldi PG, Borea PA. Modulation of the Akt/Ras/Raf/MEK/ERK pathway by A₃
adenosine receptor. Purinergic Signal. 2006 Nov;2(4):627-32. Epub 2006 Jul 26.
PubMed PMID: 18404465; PubMed Central PMCID: PMC2096659.

26. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S,
Borea PA. Adenosine modulates vascular endothelial growth factor expression via
hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol. 2006
Jun 28;72(1):19-31. Epub 2006 Mar 29. PubMed PMID: 16682012.

27. Vitale M, Gobbi G, Mirandola P, Ponti C, Sponzilli I, Rinaldi L, Manzoli FA.
TNF-related apoptosis-inducing ligand (TRAIL) and erythropoiesis: a role for PKC
epsilon. Eur J Histochem. 2006 Jan-Mar;50(1):15-8. Review. PubMed PMID: 16584980.

28. Mirandola P, Sponzilli I, Solenghi E, Micheloni C, Rinaldi L, Gobbi G, Vitale
M. Down-regulation of human leukocyte antigen class I and II and beta
2-microglobulin expression in human herpesvirus-7-infected cells. J Infect Dis.
2006 Apr 1;193(7):917-26. Epub 2006 Feb 24. PubMed PMID: 16518752.

29. Rinaldi L, Gobbi G, Pambianco M, Micheloni C, Mirandola P, Vitale M. Hydrogen
sulfide prevents apoptosis of human PMN via inhibition of p38 and caspase 3. Lab
Invest. 2006 Apr;86(4):391-7. PubMed PMID: 16446703.

30. Mirandola P, Sponzilli I, Gobbi G, Marmiroli S, Rinaldi L, Binazzi R, Piccari
GG, Ramazzotti G, Gaboardi GC, Cocco L, Vitale M. Anticancer agents sensitize
osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP
family proteins. Int J Oncol. 2006 Jan;28(1):127-33. PubMed PMID: 16327988.

31. Mirandola P, Gobbi G, Ponti C, Sponzilli I, Cocco L, Vitale M. PKCepsilon
controls protection against TRAIL in erythroid progenitors. Blood. 2006 Jan
15;107(2):508-13. Epub 2005 Sep 15. PubMed PMID: 16166586.

32. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, MacLennan S,
Baraldi PG, Borea PA. A3 adenosine receptors modulate hypoxia-inducible
factor-1alpha expression in human A375 melanoma cells. Neoplasia. 2005
Oct;7(10):894-903. PubMed PMID: 16242072; PubMed Central PMCID: PMC1502026.

33. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S,
Borea PA. A3 adenosine receptor activation inhibits cell proliferation via
phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular
signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol
Chem. 2005 May 20;280(20):19516-26. Epub 2005 Mar 17. PubMed PMID: 15774470.

34. Gobbi G, Mirandola P, Micheloni C, Solenghi E, Sponzilli I, Artico M, Soda G,
Zanelli G, Pelusi G, Fiorini T, Cocco L, Vitale M. Expression of HLA class I
antigen and proteasome subunits LMP-2 and LMP-10 in primary vs. metastatic breast
carcinoma lesions. Int J Oncol. 2004 Dec;25(6):1625-9. PubMed PMID: 15547699.

35. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Melloni E, Vitale M. The response
of human natural killer cells to interleukin-2. J Endocrinol Invest. 2004;27(6
Suppl):146-50. Review. PubMed PMID: 15481816.

36. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L, Zauli G,
Secchiero P, Manzoli FA, Vitale M. Activated human NK and CD8+ T cells express
both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are
resistant to TRAIL-mediated cytotoxicity. Blood. 2004 Oct 15;104(8):2418-24. Epub
2004 Jun 17. PubMed PMID: 15205263.

37. Gobbi G, Mirandola P, Tazzari PL, Talarico E, Caimi L, Martini G, Papa S,
Conte R, Manzoli FA, Vitale M. New laboratory test in flow cytometry for the
combined analysis of serologic and cellular parameters in the diagnosis of
heparin-induced thrombocytopenia. Cytometry B Clin Cytom. 2004 Mar;58(1):32-8.
PubMed PMID: 14994373.

38. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA,
Borea PA. A glance at adenosine receptors: novel target for antitumor therapy.
Pharmacol Ther. 2003 Oct;100(1):31-48. Review. PubMed PMID: 14550503.

39. Merighi S, Mirandola P, Varani K, Gessi S, Capitani S, Leung E, Baraldi PG,
Tabrizi MA, Borea PA. Pyrazolotriazolopyrimidine derivatives sensitize melanoma
cells to the chemotherapic drugs: taxol and vindesine. Biochem Pharmacol. 2003
Sep 1;66(5):739-48. PubMed PMID: 12948854.

40. Gobbi G, Mirandola P, Tazzari PL, Ricci F, Caimi L, Cacchioli A, Papa S,
Conte R, Vitale M. Flow cytometry detection of serotonin content and release in
resting and activated platelets. Br J Haematol. 2003 Jun;121(6):892-6. PubMed
PMID: 12786800.

41. Merighi S, Baraldi P.G, Gessi S, Iannotta V, Klotz K.N, Leung E, Mirandola P, Tabrizi M.A, Varani K, Borea P.A (2003). Adenosine Receptors and Human Melanoma.. Drug Development Research 2033;58:377-385. ISSN: 1098-2299, doi: 10.1002/ddr.10181

42. Gonelli A, Mirandola P, Grill V, Secchiero P, Zauli G. Human herpesvirus 7
infection impairs the survival/differentiation of megakaryocytic cells.
Haematologica. 2002 Nov;87(11):1223-5. PubMed PMID: 12414354.

43. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, Leung E,
Baraldi PG, Borea PA. Adenosine receptors as mediators of both cell proliferation
and cell death of cultured human melanoma cells. J Invest Dermatol. 2002
Oct;119(4):923-33. PubMed PMID: 12406340.

44. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, Milani
D, Zauli G. Tumor necrosis factor-related apoptosis-inducing ligand induces
monocytic maturation of leukemic and normal myeloid precursors through a
caspase-dependent pathway. Blood. 2002 Oct 1;100(7):2421-9. PubMed PMID:
12239152.

45. Vitale M, Bassini A, Secchiero P, Mirandola P, Ponti C, Zamai L, Mariani AR,
Falconi M, Azzali G. NK-active cytokines IL-2, IL-12, and IL-15 selectively
modulate specific protein kinase C (PKC) isoforms in primary human NK cells. Anat
Rec. 2002 Feb 1;266(2):87-92. PubMed PMID: 11788941.
-------------------------------------------------------------------------------------------------------------------
Publications prior to the last 10 years (1992-2001)
n°=27; IF2010 cumulativo >207,7

46. Skrincosky D, Willis RA, Hocknell PK, Frelinger JG, Mirandola P, Wang X,
Dewhurst S. Epitope mapping of human herpesvirus-7 gp65 using monoclonal
antibodies. Arch Virol. 2001;146(9):1705-22. PubMed PMID: 11699957.

47. Secchiero P, Mirandola P, Zella D, Celeghini C, Gonelli A, Vitale M, Capitani
S, Zauli G. Human herpesvirus 7 induces the functional up-regulation of tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1
down-modulation in CD4(+) T cells. Blood. 2001 Oct 15;98(8):2474-81. PubMed PMID:
11588045.

48. Secchiero P, Gonelli A, Celeghini C, Mirandola P, Guidotti L, Visani G,
Capitani S, Zauli G. Activation of the nitric oxide synthase pathway represents a
key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated
cytotoxicity on hematologic malignancies. Blood. 2001 Oct 1;98(7):2220-8. PubMed
PMID: 11568010.

49. Curreli S, Romerio F, Mirandola P, Barion P, Bemis K, Zella D. Human primary
CD4 + T cells activated in the presence of IFN-alpha 2b express functional
indoleamine 2,3-dioxygenase. J Interferon Cytokine Res. 2001 Jun;21(6):431-7.
PubMed PMID: 11440641.

50. Zauli G, Milani D, Mirandola P, Mazzoni M, Secchiero P, Miscia S, Capitani S.
HIV-1 Tat protein down-regulates CREB transcription factor expression in PC12
neuronal cells through a phosphatidylinositol 3-kinase/AKT/cyclic nucleoside
phosphodiesterase pathway. FASEB J. 2001 Feb;15(2):483-91. PubMed PMID: 11156964.

51. Secchiero P, Zella D, Curreli S, Mirandola P, Capitani S, Gallo RC, Zauli G.
Engagement of CD28 modulates CXC chemokine receptor 4 surface expression in both
resting and CD3-stimulated CD4+ T cells. J Immunol. 2000 Apr 15;164(8):4018-24.
PubMed PMID: 10754293.

52. Secchiero P, Zella D, Curreli S, Mirandola P, Capitani S, Gallo RC, Zauli G.
Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4+ T cell
hyperactivation and HIV type 1 replication. Proc Natl Acad Sci U S A. 2000 Dec
19;97(26):14620-5. PubMed PMID: 11114167; PubMed Central PMCID: PMC18968.

53. Mirandola P, Secchiero P, Pierpaoli S, Visani G, Zamai L, Vitale M, Capitani
S, Zauli G. Infection of CD34(+) hematopoietic progenitor cells by human
herpesvirus 7 (HHV-7). Blood. 2000 Jul 1;96(1):126-31. PubMed PMID: 10891440.

54. Colamussi ML, Secchiero P, Zella D, Curreli S, Mirandola P, Capitani S, Zauli
G. Stromal derived factor-1alpha induces apoptosis in activated primary CD4+ T
cells. AIDS. 2000 Apr 14;14(6):748-50. PubMed PMID: 10807201.

55. Zauli G, Secchiero P, Rodella L, Gibellini D, Mirandola P, Mazzoni M, Milani
D, Dowd DR, Capitani S, Vitale M. HIV-1 Tat-mediated inhibition of the tyrosine
hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem. 2000 Feb
11;275(6):4159-65. PubMed PMID: 10660577.

56. Mirandola P, Stefan A, Brambilla E, Campadelli-Fiume G, Grimaldi LM. Absence
of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis
patients. Neurology. 1999 Oct 12;53(6):1367-8. PubMed PMID: 10522909.

57. Mischiati C, Pironi F, Milani D, Giacca M, Mirandola P, Capitani S, Zauli G.
Extracellular HIV-1 Tat protein differentially activates the JNK and ERK/MAPK
pathways in CD4 T cells. AIDS. 1999 Sep 10;13(13):1637-45. PubMed PMID: 10509564.

58. Campadelli-Fiume G, Mirandola P, Menotti L. Human herpesvirus 6: An emerging
pathogen. Emerg Infect Dis. 1999 May-Jun;5(3):353-66. Review. PubMed PMID:
10341172; PubMed Central PMCID: PMC2640789.

59. Menotti L, Mirandola P, Locati M, Campadelli-Fiume G. Trafficking to the
plasma membrane of the seven-transmembrane protein encoded by human herpesvirus 6
U51 gene involves a cell-specific function present in T lymphocytes. J Virol.
1999 Jan;73(1):325-33. PubMed PMID: 9847336; PubMed Central PMCID: PMC103837.

60. Cocchi F, Menotti L, Mirandola P, Lopez M, Campadelli-Fiume G. The ectodomain
of a novel member of the immunoglobulin subfamily related to the poliovirus
receptor has the attributes of a bona fide receptor for herpes simplex virus
types 1 and 2 in human cells. J Virol. 1998 Dec;72(12):9992-10002. PubMed PMID:
9811737; PubMed Central PMCID: PMC110516.

61. Kempf W, Adams V, Mirandola P, Menotti L, Di Luca D, Wey N, Müller B,
Campadelli-Fiume G. Persistence of human herpesvirus 7 in normal tissues detected
by expression of a structural antigen. J Infect Dis. 1998 Sep;178(3):841-5.
PubMed PMID: 9728555.

62. Mirandola P, Menegazzi P, Merighi S, Ravaioli T, Cassai E, Di Luca D.
Temporal mapping of transcripts in herpesvirus 6 variants. J Virol. 1998
May;72(5):3837-44. PubMed PMID: 9557667; PubMed Central PMCID: PMC109607.

63. Mirandola P, Ravaioli T, Cassai E. PCR analysis of human telomeric repeats
present on HHV-6A viral strains. Virus Genes. 1997;15(1):29-32. PubMed PMID:
9354266.

64. Di Luca D, Mirandola P, Ravaioli T, Bigoni B, Cassai E. Distribution of HHV-6
variants in human tissues. Infect Agents Dis. 1996 Oct;5(4):203-14. Review.
PubMed PMID: 8884365.

65. Dolcetti R, Di Luca D, Carbone A, Mirandola P, De Vita S, Vaccher E,
Sighinolfi L, Gloghini A, Tirelli U, Cassai E, Boiocchi M. Human herpesvirus 6 in
human immunodeficiency virus-infected individuals: association with early
histologic phases of lymphadenopathy syndrome but not with malignant
lymphoproliferative disorders. J Med Virol. 1996 Apr;48(4):344-53. PubMed PMID:
8699167.

66. Di Luca D, Zorzenon M, Mirandola P, Colle R, Botta GA, Cassai E. Human
herpesvirus 6 and human herpesvirus 7 in chronic fatigue syndrome. J Clin
Microbiol. 1995 Jun;33(6):1660-61. PubMed PMID: 7650209; PubMed Central PMCID:
PMC228240.

67. Di Luca D, Mirandola P, Ravaioli T, Dolcetti R, Frigatti A, Bovenzi P,
Sighinolfi L, Monini P, Cassai E. Human herpesviruses 6 and 7 in salivary glands
and shedding in saliva of healthy and human immunodeficiency virus positive
individuals. J Med Virol. 1995 Apr;45(4):462-8. PubMed PMID: 7666047.

68. Portolani M, Cermelli C, Mirandola P, Di Luca D. Isolation of human
herpesvirus 7 from an infant with febrile syndrome. J Med Virol. 1995
Mar;45(3):282-3. PubMed PMID: 7775948.

69. Dolcetti R, Di Luca D, Mirandola P, De Vita S, De Re V, Carbone A, Tirelli U,
Cassai E, Boiocchi M. Frequent detection of human herpesvirus 6 DNA in
HIV-associated lymphadenopathy. Lancet. 1994 Aug 20;344(8921):543. PubMed PMID:
7914634.

70. Di Luca D, Dolcetti R, Mirandola P, De Re V, Secchiero P, Carbone A, Boiocchi
M, Cassai E. Human herpesvirus 6: a survey of presence and variant distribution
in normal peripheral lymphocytes and lymphoproliferative disorders. J Infect Dis.
1994 Jul;170(1):211-5. PubMed PMID: 8014502.

71. Bovenzi P, Mirandola P, Secchiero P, Strumia R, Cassai E, Di Luca D. Human
herpesvirus 6 (variant A) in Kaposi's sarcoma. Lancet. 1993 May
15;341(8855):1288-9. PubMed PMID: 8098435.

72. Di Luca D, Mirandola P, Secchiero P, Cermelli C, Aleotti A, Bovenzi P,
Portolani M, Cassai E. Characterization of human herpesvirus 6 strains isolated
from patients with exanthem subitum with or without cutaneous rash. J Infect Dis.
1992 Sep;166(3):689. PubMed PMID: 1323627.
------------------------------------------------------------------------------------------------------------------------
b) principali pubblicazioni: sono riportate le 21 pubblicazioni più citate;
Citazioni totali secondo Scopus 1351; secondo ISI 1301
b) main publications: the most cited publications are reported (21);
Scopus total citation 1351; ISI citations 1301

1. Cocchi F, Menotti L, Mirandola P, Lopez M, Campadelli-Fiume G. The ectodomain
of a novel member of the immunoglobulin subfamily related to the poliovirus
receptor has the attributes of a bona fide receptor for herpes simplex virus
types 1 and 2 in human cells. J Virol. 1998 Dec;72(12):9992-10002.
Citations (Scopus)=194; Citations (ISI)=194

2. Campadelli-Fiume G, Mirandola P, Menotti L. Human herpesvirus 6: An emerging
pathogen. Emerg Infect Dis. 1999 May-Jun;5(3):353-66. Review.
Citations (Scopus)=102; Citations (ISI)=86

3. Merighi S, Mirandola P, Varani K, Gessi S, Leung E, Baraldi PG, Tabrizi MA,
Borea PA. A glance at adenosine receptors: novel target for antitumor therapy.
Pharmacol Ther. 2003 Oct;100(1):31-48. Review.
Citations (Scopus)=91; Citations (ISI)=88

4. Di Luca D, Dolcetti R, Mirandola P, De Re V, Secchiero P, Carbone A, Boiocchi
M, Cassai E. Human herpesvirus 6: a survey of presence and variant distribution
in normal peripheral lymphocytes and lymphoproliferative disorders. J Infect Dis.
1994 Jul;170(1):211-5.
Citations (Scopus)=87; Citations (ISI)=91

5. Di Luca D, Mirandola P, Ravaioli T, Dolcetti R, Frigatti A, Bovenzi P,
Sighinolfi L, Monini P, Cassai E. Human herpesviruses 6 and 7 in salivary glands
and shedding in saliva of healthy and human immunodeficiency virus positive
individuals. J Med Virol. 1995 Apr;45(4):462-8.
Citations (Scopus)=76; Citations (ISI)=66

6. Rinaldi L, Gobbi G, Pambianco M, Micheloni C, Mirandola P, Vitale M. Hydrogen
sulfide prevents apoptosis of human PMN via inhibition of p38 and caspase 3. Lab
Invest. 2006 Apr;86(4):391-7.
Citations (Scopus)=66; Citations (ISI)=59

7. Mirandola P, Ponti C, Gobbi G, Sponzilli I, Vaccarezza M, Cocco L, Zauli G,
Secchiero P, Manzoli FA, Vitale M. Activated human NK and CD8+ T cells express
both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are
resistant to TRAIL-mediated cytotoxicity. Blood. 2004 Oct 15;104(8):2418-24.
Citations (Scopus)=62; Citations (ISI)=60

8. Merighi S, Mirandola P, Milani D, Varani K, Gessi S, Klotz KN, Leung E,
Baraldi PG, Borea PA. Adenosine receptors as mediators of both cell proliferation
and cell death of cultured human melanoma cells. J Invest Dermatol. 2002
Oct;119(4):923-33.
Citations (Scopus)=61; Citations (ISI)=61

9. Secchiero P, Gonelli A, Mirandola P, Melloni E, Zamai L, Celeghini C, Milani
D, Zauli G. Tumor necrosis factor-related apoptosis-inducing ligand induces
monocytic maturation of leukemic and normal myeloid precursors through a
caspase-dependent pathway. Blood. 2002 Oct 1;100(7):2421-9.
Citations (Scopus)=57; Citations (ISI)=58

10. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S,
Borea PA. A3 adenosine receptor activation inhibits cell proliferation via
phosphatidylinositol 3-kinase/Akt-dependent inhibition of the extracellular
signal-regulated kinase 1/2 phosphorylation in A375 human melanoma cells. J Biol
Chem. 2005 May 20;280(20):19516-26.
Citations (Scopus)=57; Citations (ISI)=52

11. Secchiero P, Gonelli A, Celeghini C, Mirandola P, Guidotti L, Visani G,
Capitani S, Zauli G. Activation of the nitric oxide synthase pathway represents a
key component of tumor necrosis factor-related apoptosis-inducing ligand-mediated
cytotoxicity on hematologic malignancies. Blood. 2001 Oct 1;98(7):2220-8.
Citations (Scopus)=55; Citations (ISI)=54

12. Mirandola P, Stefan A, Brambilla E, Campadelli-Fiume G, Grimaldi LM. Absence
of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis
patients. Neurology. 1999 Oct 12;53(6):1367-8.
Citations (Scopus)=51; Citazion (ISI)=47

13. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L, Cocco L, Vitale
M. NK cells and cancer. J Immunol. 2007 Apr 1;178(7):4011-6. Review.
Citations (Scopus)=50; Citations (ISI)=47

14. Portolani M, Cermelli C, Mirandola P, Di Luca D. Isolation of human
herpesvirus 7 from an infant with febrile syndrome. J Med Virol. 1995
Mar;45(3):282-3.
Citations (Scopus)=50; Citations (ISI)=34

15. Mirandola P, Menegazzi P, Merighi S, Ravaioli T, Cassai E, Di Luca D.
Temporal mapping of transcripts in herpesvirus 6 variants. J Virol. 1998
May;72(5):3837-44.
Citations (Scopus)=46; Citations (ISI)=53

16. Di Luca D, Zorzenon M, Mirandola P, Colle R, Botta GA, Cassai E. Human
herpesvirus 6 and human herpesvirus 7 in chronic fatigue syndrome. J Clin
Microbiol. 1995 Jun;33(6):1660-61.
Citations (Scopus)=46; Citations (ISI)=42

17. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Leung E, Maclennan S,
Borea PA. Adenosine modulates vascular endothelial growth factor expression via
hypoxia-inducible factor-1 in human glioblastoma cells. Biochem Pharmacol. 2006
Jun 28;72(1):19-31.
Citations (Scopus)=43; Citations (ISI)=40

18. Merighi S, Benini A, Mirandola P, Gessi S, Varani K, Simioni C, Leung E,
Maclennan S, Baraldi PG, Borea PA. Caffeine inhibits adenosine-induced
accumulation of hypoxia-inducible factor-1alpha, vascular endothelial growth
factor, and interleukin-8 expression in hypoxic human colon cancer cells. Mol
Pharmacol. 2007 Aug;72(2):395-406.
Citations (Scopus)=41; Citations (ISI)=38

19. Zauli G, Secchiero P, Rodella L, Gibellini D, Mirandola P, Mazzoni M, Milani
D, Dowd DR, Capitani S, Vitale M. HIV-1 Tat-mediated inhibition of the tyrosine
hydroxylase gene expression in dopaminergic neuronal cells. J Biol Chem. 2000 Feb
11;275(6):4159-65.
Citations (Scopus)=41; Citations (ISI)=40

20. Kempf W, Adams V, Mirandola P, Menotti L, Di Luca D, Wey N, Müller B,
Campadelli-Fiume G. Persistence of human herpesvirus 7 in normal tissues detected
by expression of a structural antigen. J Infect Dis. 1998 Sep;178(3):841-5.
Citations (Scopus)=40; Citations (ISI)=38

21. Bovenzi P, Mirandola P, Secchiero P, Strumia R, Cassai E, Di Luca D. Human herpesvirus 6 (variant A) in Kaposi's sarcoma. Lancet. 1993 May 15;341(8855):1288-9.
Citations (Scopus)=35; Citations (ISI)=53
--------------------------------------------------------------------------------------------------------------
3. Titles:
a) Coordination of international and national scientific research projects, admitted
funded after peer review;

2002 Progetto Giovani Ricercatori e Ricercatori Singoli, Università di Parma
2004 Fondo FIN (ex quota 40%) e FIL (ex quota 60%) - anno 2004
2005-2007 PRIN 2005 (MIUR), “Functional role of IL-4 receptor mutations on signaling and activation of lymphocytes in osteoarthritis”. Coordinatore Nazionale: Riccardo Meliconi, Laboratori di Genetica ed Immunogia, Istititi Ortopedici Rizzoli, Bologna. Ruolo del Prof. Mirandola: Responsabile dell’Unità di Ricerca di Parma. Part of the scientific results of the project have been published in: J Immunol. 2007;178:4011-6, J Cell Physiol 2007;213:826-33.
2006 Fondo FIN (ex quota 40%) e FIL (ex quota 60%) – anno 2006 (60A05-8144); “TNF-alpha controls FHIT protein family apoptogenic effects in lung cancer cell.”. Ruolo del Prof. Mirandola: Responsabile del finanziamento. Part of the scientific results of the project have been published in: J Cell Phys. 2009;220:492-8.
2007 Fondo FIN (ex quota 40%) e FIL (ex quota 60%) – anno 2007 (FIL0719884); “TRAIL effects on hypoxic human tumor cells”. Ruolo del Prof. Mirandola: Responsabile del finanziamento. Part of the scientific results of the project have been published in: Int J Oncol Int J Oncol. 2010 Sep;37(3):719-29.

b)Component of directive board of magazines, collections of books, encyclopedias and treatises of recognized prestige;
no

c) Participation in editorial boards of journals, collections of books, encyclopedias and
Treaties of prestige;

d) assignment of teaching duties or research (fellowship) at foreign, international, highly qualified the universities and research institutions;
1993-1994 Fellow C.N.R., progetto “F.A.T.M.A.”, at the Istituto di Microbiologia, Università di Ferrara.
1994-1996 Fellow I.S.S., progetto “AIDS Italia”, at the Istituto di Microbiologia, Università di Ferrara.
1996-1997 Fellow, (renewal) I.S.S., progetto “AIDS Italia”, at the Istituto di Microbiologia, Università di Ferrara.
1997-1999 Fellow U.E., progetto “Malattie infettive ed AIDS”, at the Dipartimento di Patologia Sperimentale, Università di Bologna.
1999-2000 Post. Doc. Fellow at the University of Maryland Biotechnology Institute (Baltimora, USA);

e) Component of direction board of of internationally high quality research institutions;
no

f) participation in academies having prestige in the sector;
no

g) awards for scientific activity;
2000 Cecilia Cioffrese award of the Fondazione Carlo Erba for studies and research in the field of health care, cancer and viral diseases

h) results obtained in the transfer technology, creation of new enterprises (spin off),
development, use and commercialization of patents;
no

i) i) other qualifications that contribute to a better definition of the scientific profile of the
candidate.
CELLULAR AND MOLECULAR BIOLOGY PhD at Dipartimento di Morfologia ed Embriologia, Università di Ferrara (2001).
As co-worker has contributed and participated in the following research programs:
2010-2012 “Pharmacological characterization of nucleosides as potential modulators of erythropoietin production and effects”. SCIENTIFIC RESEARCH GRANTS – 2009; FINANZIATO DA WORLD ANTI-DOPING AGENCY. Applicants: Pier Andrea Borea (Dipartimento di Medicina Clinica e Sperimentale, Università di Ferrara) e Marco Vitale (Dipartimento di Anatomia Umana, Farmacologia e Scienze Medico Forensi, Università di Parma)
2007-2009 "Tissue engineering in osteoarticular disease: basic and clinical evaluation". RICERCA FINALIZZATA REGIONE-UNIVERSITÀ 2007-2009. FINANZIATO DAL MINISTERO DELLA SALUTE.
Applicants: Facchini Andrea (Dipartimento di Medicina Interna e Gastroenterologia, Università di Bologna) e Marco Vitale (Dipartimento di Anatomia Umana, Farmacologia e Scienze Medico Forensi, Università di Parma)
2007-2009 "Therapeutic applications of stem cells in the treatment of heart failure". PROGETTO ORDINARIO RICERCA FINALIZZATA REGIONE-UNIVERSITÀ 2007-2009, SUPPORTATO DELLA REGIONE EMILIA ROMAGNA (SERVIZIO SANITARIO NAZIONALE).
Coordinator: Tiziano Gherli (Direttore della Struttura Complessa di Cardiochirurgia, Dipartimento Cardio-polmonare, dell'Azienda Ospedaliero-Universitaria di Parma). Unit Research PI: Marco Vitale (Dipartimento di Anatomia Umana, Farmacologia e Scienze Medico Forensi, Università di Parma).
2005-2008 “Role of the TNF-related apoptosis-inducing ligand (TRAIL) in the control of lung cancer disease by the tumor-suppressor gene FHIT.” PHILIP MORRIS EXTERNAL RESEARCH PROGRAM (2004). Coordinator: Marco Vitale (Dipartimento di Anatomia Umana, Farmacologia e Scienze Medico Forensi, Università di Parma).
2010-2013 “Pathogenesis and molecular targets in degenerative muscoskeletal diseases”.ACCORDO EX ART.7 DEL D.M. 378 DEL 26/03/04. FIRB 2010.
Coordinator: Andrea Facchini (Dipartimento di Medicina Clinica, Policlinico S. Orsola Malpighi, Padiglione 5, Via Massarenti 9, Bologna).
Unit Research PI: Marco Vitale (Dipartimento di Anatomia Umana, Farmacologia e Scienze Medico Forensi, Università di Parma).
2012-under review “A tailored approach to the immune-monitoring and clinical management of
viral and autoimmune diseases”. PROGRAMMA DI RICERCA REGIONE-UNIVERSITÀ 2010-2012 (AREA 1 – STRATEGIC PROGRAMMES).
Coordinator: Carlo Ferrari (Azienda Ospedaliero-Universitaria di Parma)
Work package PI: Prisco Mirandola (Dipartimento di Anatomia Umana, Farmacologia e Scienze Medico Forensi, Università di Parma)
------------------------------------------------------------------------------------------------------------------
4: Teaching:
TEACHING ASSIGNMENTS

• 00035 - ANATOMIA UMANA - HUMAN ANATOMY
Course of studyo: 0268 - CHIMICA E TECNOLOGIA FARMACEUTICHE Regulation Year: 2007 Percorso: GEN - CORSO GENERICO
CFU: 5.0 Settore: BIO/16 Activity type: A - Base
Coverage type: SUP12 - Prof. Supplente retribuito ex art. 114
Activity start date: 21/04/2008 Activity end date: 30/05/2008

• 00035 - ANATOMIA UMANA - HUMAN ANATOMY
Course of studyo: 0354 - TEC.PREV.AMB. E LUOGHI LAV.(ABIL.PROF.SAN.TECN.PREV.AMB.E LUOGHI LAV.) Regulation Year: 2007, 2008,2009,2010 Percorso: GEN - CORSO GENERICO
CFU: 2.0 Settore: BIO/16 Activity type: A - Base
Coverage type: AFF04 - Free award ex art.9/V
Activity start date: 01/11/2007 Activity end date: 31/10/2008
Coverage type: AFF04 - Free award ex art.9/V
Activity start date: 01/11/2008 Activity end date: 31/10/2009
Coverage type: AFF04 - Free award ex art.9/V
Activity start date: 01/11/2009 Activity end date: 31/10/2010
Coverage type: AFF04 - Free award ex art.9/V
Activity start date: 01/11/2010 Activity end date: 31/10/2011

• 14302 - ANATOMIA UMANA (C) - HUMAN ANATOMY (C)
Course of studyo: 0269 - MEDICINA E CHIRURGIA Regulation Year: 2007,2008 Percorso: GEN - CORSO GENERICO
CFU: 3.0 Settore: BIO/16 Activity type: C - Affine/Integrativa
Coverage type: RESPD - Responsabilita' didattica
Activity start date: 01/11/2007 Activity end date: 31/10/2008
Coverage type: RESPD - Responsabilita' didattica
Activity start date: 01/11/2008 Activity end date: 31/10/2009

• 14408 - ANATOMIA UMANA (FR) - HUMAN ANATOMY (ATT)
Course of studyo: 0269 - MEDICINA E CHIRURGIA Regulation Year: 2007,2008 Percorso: GEN - CORSO GENERICO
CFU: 6.0 Settore: BIO/16 Activity type: A - Base
Coverage type RESPD - Responsabilita' didattica
Activity start date: 01/11/2007 Activity end date: 31/10/2008
Coverage type: RESPD - Responsabilita' didattica
Activity start date: 01/11/2008 Activity end date: 31/10/2009

• 08614 - ANATOMIA UMANA - HUMAN ANATOMY
Course of studyo: 5026 - MEDICINA E CHIRURGIA Regulation Year: 2009,2010,2011 Percorso: GEN - CORSO GENERICO
CFU: 7.0 Settore: BIO/16 Activity type: A - Base
Coverage type: RESPD - Responsabilita' didattica
Activity start date: 01/03/2010 Activity end date: 31/05/2010
Coverage type: RESPD - Responsabilita' didattica
Activity start date: 01/03/2011 Activity end date: 31/05/2011
Coverage type: RESPD - Responsabilita' didattica
Activity start date: 01/03/2012 Activity end date: 31/05/2012

• 1000236 - TECNICHE DI SELEZIONE, MANTENIMENTO E DIFFERENZIAZIONE DI CELLULE STAMINALI MOD. A - TECHNIQUES FOR STEM CELL SELECTION
Course of studyo: 1109 - BIOTECNOLOGIE MEDICHE, VETERINARIE E FARMACEUTICHE Regulation Year: 2007,2008 Percorso: 220 - BIOTECNOLOGIE APPLICATE ALLA MEDICINA RIGENERATIVA E RIPARATIVA
CFU: 2.0 Settore: BIO/16 Activity type: A - Base
Coverage type: AFF04 - Free award ex art.9/V
Activity start date: 01/11/2007 Activity end date: 31/10/2008
Coverage type: AFF04 - Free award ex art.9/V
Activity start date: 01/11/2008 Activity end date: 31/10/2009

• 1002972 - ANATOMIA UMANA mod. D - HUMAN ANATOMY UNIT D
Course of studyo: 3019 - SCIENZE MOTORIE, SPORT E SALUTE Regulation Year: 2009,2010 Percorso: GEN - CORSO GENERICO
CFU: 1.0 Settore: BIO/16 Activity type: A - Base
Coverage type: AFF04 - Free award ex art.9/V
Activity start date: 01/10/2009 Activity end date: 29/01/2010
Coverage type: AFF04 - Free award ex art.9/V
Activity start date: 01/10/2010 Activity end date: 29/01/2011

• 1002396 - MORFOLOGIA FUNZIONALE DELLA RIGENERAZIONE TISSUTALE - FUNCTIONAL MORPHOLOGY OF TISSUE REGENERATION
Course of studyo: 5045 - BIOTECNOLOGIE MEDICHE, VETERINARIE E FARMACEUTICHE Regulation Year: 2009,2010 Percorso: 321 - Biotecnologie applicate alla medicina rigenerativa e ripartiva
CFU: 1.0 Settore: BIO/16 Activity type: B - Caratterizzante
Coverage type: AFF04 - Free award ex art.9/V
Activity start date: 01/03/2010 Activity end date: 31/05/2010
Coverage type: AFF04 - Free award ex art.9/V
Activity start date: 01/03/2011 Activity end date: 31/05/2011

• 08249 - ANATOMIA ED ISTOLOGIA - ANATOMY AND HISTOLOGY
Course of studyo: 3048 - Tecniche di radiologia medica, per immagini e radioterapia (abilitante alla professione sanitaria di Tecnico di radiologia medica) Regulation Year: 2011 Percorso: GEN - CORSO GENERICO
CFU: 5.0 Settore: BIO/16 Activity type: A - Base
Coverage type: AFF12 - Affidam. Proff. I - II Fascia - L.240/10
Activity start date: 03/10/2011 Activity end date: 31/01/2012

• 21952 - ANATOMIA UMANA - HUMAN ANATOMY
Course of studyo: 3049 - Tecniche della prevenzione nell'ambiente e nei luoghi di lavoro (abilitante alla professione sanitaria di Tecnico della prevenzione nell'ambiente e nei luoghi di lavoro) Regulation Year: 2011 Percorso: GEN - CORSO GENERICO
CFU: 2.0 Settore: BIO/16 Activity type: A - Base
Coverage type: AFF12 - Affidam. Proff. I - II Fascia - L.240/10
Activity start date: 03/10/2011 Activity end date: 31/01/2012
-------------------------------------------------------------------------------------------------------------------------
RESPONSABILITÀ DIDATTICHE

• 17013 - SCIENZE BIOMEDICHE (ANATOMIA, CITOLOGIA, FISIOLOGIA) - BIOMEDICAL SCIENCES (ANATOMY, CYTOLOGY, PHYSIOLOGY)
Course of studyo: 0354 - TEC.PREV.AMB. E LUOGHI LAV.(ABIL.PROF.SAN.TECN.PREV.AMB.E LUOGHI LAV.) Regulation Year: 2007,2008,2009,2010 Percorso: GEN - CORSO GENERICO
CFU: 6.0

• 15416 - SCIENZE BIOMEDICHE - BIOMEDICAL SCIENCES
Course of studyo: 3049 - Tecniche della prevenzione nell'ambiente e nei luoghi di lavoro (abilitante alla professione sanitaria di Tecnico della prevenzione nell'ambiente e nei luoghi di lavoro) Regulation Year: 2011 Percorso: GEN - CORSO GENERICO
CFU: 6.0

• 15459 - ANATOMIA UMANA E FISIOLOGIA - HUMAN ANATOMY AND PHYSIOLOGY
Course of studyo: 3048 - Tecniche di radiologia medica, per immagini e radioterapia (abilitante alla professione sanitaria di Tecnico di radiologia medica) Regulation Year: 2011 Percorso: GEN - CORSO GENERICO
CFU: 7.0
---------------------------------------------------------------------------------------------------------------------
Internship and training students and undergraduates
Intense effort, as tutor and supervisor, was spent to the research activity of many students of different courses of bachelor degree, master's degree of the Faculty of Medicine and of Mathematical, Physical and Natural Sciences. Experimental/practical and compilatory thesis for undergraduate students of Corso di Laurea Specialistica in Biotecnologie per la Salute; Corso di Laurea Magistrale in Biotecnologie Mediche, Veterinarie e Farmaceutiche; Corso di Laurea in Biotecnologie; Corso di Laurea in Scienze delle Attività Motorie; Corso di Laurea Magistrale in Scienze e Tecniche delle Attività Motorie Preventive e Adattate, were done.

Completion accademic year: 2019/2020

Completion accademic year: 2018/2019

Completion accademic year: 2017/2018

Completion accademic year: 2016/2017

Completion accademic year: 2015/2016

Completion accademic year: 2014/2015

Completion accademic year: 2013/2014

Professor/Teacher

Publications

Contacts

Phone number
033052